Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.

Additionally, the Department of Health and Human Services unveiled the framework for the Most Favored Nation drug pricing plan announced last week by President Donald Trump.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The US Food and Drug Administration changes Covid-19 vaccine approval process. Access to seasonal boosters is restricted for healthy individuals under 65. This decision contrasts with previous recommendations for annual shots for all.

The FDA finally approved Novavax's Covid-19 vaccine, but placed restrictions on it that its two competitors in the U.S. do not face